Journal article
Beneficial aspects of high dose intravenous vitamin C on patients with COVID-19 pneumonia in severe condition: a retrospective case series study
Annals of palliative medicine, Vol.10(2), pp.1599-11
02/01/2021
DOI: 10.21037/apm-20-1387
PMID: 33222462
Abstract
Coronavirus disease 2019 (COVID-19) is a global public health event without specific therapeutic agents till now. We aim to determine if high dose intravenous vitamin C (HDIVC) was effective for COVID-19 patients in severe condition.
COVID-19 patients admitted in Shanghai Public Health Clinical Center from January 22, 2020 to April 11, 2020 were retrospectively scrolled. The enrolled patients were those with confirmed diagnosis of severe or critical COVID-19 pneumonia, who received HDIVC within 24 hours after disease aggravation. Main clinical outcomes obtained from 3-5 days (day 3) and 7-10 days (day 7) after HDIVC were compared to the ones just before (day 0) HDIVC.
Totally, twelve patients were enrolled including six severe [age of mean, 56; interquartile range (IQR), 32-65 years, 3 men] and six critical (age of mean, 63; IQR, 60-82 years, 4 men) patients. The dosage of vitamin C [median (IQR), mg/kg (body weight)/day] were [162.7 (71.1-328.6)] for severe and [178.6 (133.3-350.6)] for critical patients. By Generalized estimating equation (GEE) model, C-reactive protein (CRP) was found to decrease significantly from day 0 to 3 and 7 (severe: 59.01±37.9, 12.36±22.12, 8.95±20.4; critical: 92.5±41.21, 33.9±30.2, 59.56±41.4 mg/L). Lymphocyte and CD4+ T cell counts in severe patients reached to normal level since day 3. Similar improving trends were observed for PaO2/FiO2 (severe: 209.3±111.7, 313.4±146, 423.3±140.8; critical: 119.9±52.7, 201.8±86.64, 190.5±51.99) and sequential organ failure assessment score (severe: 2.83±1.72, 1.33±1.63, 0.67±1.03; critical: 6.67±2.34, 4.17±2.32, 3.83±2.56). Better improving effect was observed in severe than critical patients after HDIVC.
HDIVC might be beneficial in aspects of inflammatory response, immune and organ function for aggravation of COVID-19 patients. Further clinical trials are in warrant.
This trial has been retrospectively registered in Chinese Clinical Trail Registry (ChiCTR2000032716) on May 8, 2020. http://www.chictr.org.cn/showproj.aspx?proj=53389.
Details
- Title: Subtitle
- Beneficial aspects of high dose intravenous vitamin C on patients with COVID-19 pneumonia in severe condition: a retrospective case series study
- Creators
- Bing Zhao - Ruijin HospitalYun Ling - Shanghai Public Health Clinical CenterJian Li - Ruijin HospitalYibing Peng - Ruijin HospitalJun Huang - Shanghai Institute of HypertensionYihui Wang - Ruijin HospitalHongping Qu - Ruijin HospitalYuan Gao - Renji HospitalYingchuan Li - Shanghai Sixth People's HospitalBijie Hu - The First Affiliated Hospital, Sun Yat-sen UniversityShuihua Lu - Shanghai Jiao Tong UniversityHongzhou Lu - Shanghai Public Health Clinical CenterWenhong Zhang - Ruijin HospitalEnqiang Mao - Ruijin Hospital
- Resource Type
- Journal article
- Publication Details
- Annals of palliative medicine, Vol.10(2), pp.1599-11
- DOI
- 10.21037/apm-20-1387
- PMID
- 33222462
- NLM abbreviation
- Ann Palliat Med
- ISSN
- 2224-5820
- eISSN
- 2224-5839
- Language
- English
- Date published
- 02/01/2021
- Academic Unit
- Internal Medicine
- Record Identifier
- 9984696753502771
Metrics
15 Record Views